San Rafael, Calif. – September 13, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reported that its Phase 3 CANOPY-HCH-3 trial of VOXZOGO (vosoritide) met its primary endpoint in children with hypochondroplasia, with results published in NEJM Evidence and presented at the European Society for Paediatric Endocrinology 2026 Annual Meeting.

Austin, Texas – – September 13, 2026 -- Moment Energy has become the first battery energy storage system (BESS) provider in North America to secure third-party verified non-Prohibited Foreign Entity (non-PFE) status and full Foreign Entity of Concern (FEOC) compliance, the company announced. A Top 10 U.S. law firm conducted the independent review, examining Moment Energy's corporate ownership, effective control and debt financing structure.

Berlin – September 13, 2026 -- Germany's largest doctors' association, the Marburger Bund, has warned lawmakers that a draft reform of emergency medical care could hand health insurers de facto control over which local emergency sites survive, ahead of a public hearing before the Bundestag's Health Committee.